Preoperative versus postoperative chemoradiation for patients with resected pancreatic

Pendurthi, Tribhuvan K.; Hoffman, John P.; Ross, Eric; Johnson, Dennis E.; Eisenberg, Burton L.
July 1998
American Surgeon;Jul1998, Vol. 64 Issue 7, p686
Academic Journal
Studies two groups of patients with adenocarcinoma of the pancreas treated with preoperative chemoradiation or postoperative chemoradiation for various treatment-related parameters. Chemotherapy regimens used with radiation therapy; Prognostic parameters for patients; Complications.


Related Articles

  • Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Halm, U; Schumann, T; Schiefke, I; Witzigmann, H; Mössner, J; Keim, V // British Journal of Cancer;3/1/2000, Vol. 82 Issue 5, p1013 

    Chemotherapy with gemcitabine has been shown to be an effective regimen in advanced or metastatic pancreatic cancer with improvement of both quality of life and survival time. The response of the tumour marker CA 19-9 to chemotherapy with gemcitabine was studied in order to find out whether it...

  • Drug `approvable' for advanced pancreatic cancer. McCann, Jean // Drug Topics;8/21/95, Vol. 139 Issue 16, p37 

    Focuses on gemcitabine, a drug used for the treatment of advanced pancreatic cancer. Rating from the Food and Drug Administration; Improvement in median survival; Side effects of the drug with brand name Gemzar from Eli Lilly; Efficacy.

  • Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. Plath, Thomas; Peters, Michael; Detjen, Katharina; Welzel, Martina; von Marschall, Zofia; Radke, Cornelia; Weidenmann, Bertram; Rosewicz, Stefan; Wiedenmann, Bertram // JNCI: Journal of the National Cancer Institute;1/16/2002, Vol. 94 Issue 2, p129 

    Background: Human pancreatic adenocarcinomas are highly resistant to chemotherapy. The p16 tumor-suppressor protein is inactivated in more than 90% of human pancreatic cancers. The p16 protein transcriptionally inhibits expression of retinoblastoma tumor-suppressor gene pRB. The pRB...

  • Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cascinu, S; Frontini, L; Comella, G; Barni, S; Labianca, R; Battelli, N; Casaretti, R; Zonato, S; Pirovano, M; Catalano, G; Cellerino, R // British Journal of Cancer;2/1/99, Vol. 79 Issue 3/4, p491 

    Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m[SUP-2], 5-fluorouracil 500 mg m[SUP-2], epidoxorubicin 35 mg m[SUP-2], 6S stereoisomer of leucovorin 250 mg m[SUP-2] and glutathione 1.5 mg...

  • Does Neoadjuvant Chemoradiation Downstage Locally Advanced Pancreatic Cancer? Kim, Hong Jin; Czischke, Karen; Brennan, Murray F.; Conlon, Kevin C. // Journal of Gastrointestinal Surgery;Sep2002, Vol. 6 Issue 5, p763 

    Recent studies suggest that neoadjuvant chemoradiation can downstage locally advanced pancreatic tumors. There is limited evaluable data to support this approach. We review our experience with preoperative chemoradiation for surgically staged, locally advanced pancreatic cancer to determine...

  • Treatment of unresectable pancreatic cancer. Carter, D.C. // British Medical Journal (Clinical Research Edition);6/12/1982, Vol. 284 Issue 6331, p1727 

    Examines the treatment of unresectable pancreatic cancer. Importance of chemotherapy and radiotherapy; Measurement of tumor response; Efficacy of palliative radiotherapy.

  • CHEMO FOR PANCREATIC CANCER. JM; Harrar, Sari // Prevention;May2002, Vol. 54 Issue 5, p162 

    Focuses on a study of people who had surgery for pancreatic cancer and the benefits of chemotherapy compared with those who did not receive such therapy.

  • Biliary stents for pancreas cancer with obstruction: the problem with plastic. Boulay, Brian R. // Journal of Gastrointestinal Oncology;Dec2012, Vol. 3 Issue 4, p306 

    The author explores the use of plastic stents in patients with pancreatic cancer undergoing neoadjuvant therapy. He cites a retrospective review of patients with plastic stents which revealed that more than half of the patients underwent unplanned stent exchange due to stent occlusion or...

  • A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cascinu, S; Silva, R R; Barni, S; Labianca, R; Frontini, L; Piazza, E; Pancera, G; Giordani, P; Giuliodori, L; Pessi, M A; Fusco, V; Luporini, G; Cellerino, R; Catalano, G // British Journal of Cancer;7/15/99, Vol. 80 Issue 10, p1595 

    In a randomized clinical trial, gemcitabine (GEM) was more effective than 5-fluorouracil (5-FU) in advanced pancreatic cancer patients. GEM and 5-FU have different mechanisms of action and their combination, from a theoretical point of view, could result in a higher activity. To test activity...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics